Finzati - Logo
BIO-B logo

Bio-Rad Laboratories, Inc.

BIO-B • Medical - Devices
$386.11
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$10.35B
Growth
7.6%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 29.4%Positive free cash flow · 13.74Consistent free cash flow · 5/5Reasonable earnings multiple · 10.87Manageable debt level · 0.21
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 6, 2026, 12:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$386.11
Change0.00%
Shares Out26.81M
Market Cap$10.35B
Enterprise Value$9.94B
52W Range244.54 - 337.00
Beta1.12
P/E46.55
P/S4.00
P/B1.44
P/FCF29.32
EV/Sales3.84

Investment DNA

How strong this company looks for long-term investors

69
out of 100
Business Quality
Margins, moat, returns
69/100
Financial Strength
Debt, cash, stability
87/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
76/100
Why this score▼
Stable or improving margins · 29.4%Positive free cash flow · 13.74Consistent free cash flow · 5/5Reasonable earnings multiple · 10.87Manageable debt level · 0.21Healthy liquidity · 5.62

Analyst view

Analyst sentiment and price target

BIO
Analyst sentiment
Based on 14 analyst votes · 2026-09-04
79/100
Bullish
Bullish
8
Hold
6
Bearish
0
Price Target
2026-08-06
Low
$310.00
Mean
$338.33
Median
$335.00
High
$370.00

Company Overview

IPO: 9/21/1999
Industry: Medical - Devices
P/B i: 1.44
Debt / Equity i: 0.21
Operating Margin: 10.47%
Net Margin: 29.42%
ROE i: -
ROIC: -

Financial Health

Score17 / 20
Debt / Equity: 0.21
Current Ratio: 5.62
Quick Ratio: 4.19
Status: Strong

Insider Transactions

Recent executive and insider activity

ENGELHARDT EVA ANETTE
Transaction: 07/25/2026
SELL
Change
-246
Price
Not reported
Filing
07/28/2026
Type
SELL
ENGELHARDT EVA ANETTE
Transaction: 07/25/2026
SELL
Change
-89
Price
$314.46
Filing
07/28/2026
Type
SELL
ENGELHARDT EVA ANETTE
Transaction: 05/11/2026
SELL
Change
-550
Price
$246.54
Filing
05/13/2026
Type
SELL